Non-Small Cell Lung Cancer — Global Clinical Trial Landscape (2024)

Explore cutting-edge Non-Small Cell Lung Cancer (NSCLC) research with Novotech CRO's in-depth disease analysis, providing insights into innovative therapies, clinical trials, and future directions shaping NSCLC care globally.

NSCLC, accounting for 85% of lung cancer cases, presents significant challenges, with early-stage diagnoses at 30% and varying survival rates. Globally, NSCLC affects millions annually, with Asia-Pacific leading in incidence. Treatment involves surgery, chemotherapy, and radiation, supplemented by targeted therapies and immunotherapies.

Since 2019, over 5,000 NSCLC trials have been initiated globally, led by Asia-Pacific. Marketed drugs and promising pipeline candidates, like KRAS and EGFR inhibitors, reflect evolving treatment strategies. Novotech, a top global clinical CRO, facilitates NSCLC research, supporting over 5,000 clinical projects and bioequivalence studies.

Discover more about NSCLC research advancements by accessing our comprehensive disease report today.